Univariate analysis of association between treatment option at time of admission and outcomes
| . | Corticosteroids + IVIG . | Corticosteroids + IVIG + anakinra . | P value . |
|---|---|---|---|
| (n = 169) . | (n = 21)a . | ||
| Heart involvement at the end of follow-up, n (%) | 66 (39.1) | 3 (15) | 0.047 |
| Use of vasoactive agents during hospitalization; n (%) | 21 (12.4) | 8 (40) | 0.001 |
| Need of ventilatory support, n (%) | 33 (19.5) | 7 (35) | 0.11 |
| Intensive care admittance, n (%) | 45 (26.6) | 10 (50) | 0.03 |
| . | Corticosteroids + IVIG . | Corticosteroids + IVIG + anakinra . | P value . |
|---|---|---|---|
| (n = 169) . | (n = 21)a . | ||
| Heart involvement at the end of follow-up, n (%) | 66 (39.1) | 3 (15) | 0.047 |
| Use of vasoactive agents during hospitalization; n (%) | 21 (12.4) | 8 (40) | 0.001 |
| Need of ventilatory support, n (%) | 33 (19.5) | 7 (35) | 0.11 |
| Intensive care admittance, n (%) | 45 (26.6) | 10 (50) | 0.03 |
19 patients were treated with anakinra, CSs and IVIG; 2 patients were treated with anakinra and CSs.
Univariate analysis of association between treatment option at time of admission and outcomes
| . | Corticosteroids + IVIG . | Corticosteroids + IVIG + anakinra . | P value . |
|---|---|---|---|
| (n = 169) . | (n = 21)a . | ||
| Heart involvement at the end of follow-up, n (%) | 66 (39.1) | 3 (15) | 0.047 |
| Use of vasoactive agents during hospitalization; n (%) | 21 (12.4) | 8 (40) | 0.001 |
| Need of ventilatory support, n (%) | 33 (19.5) | 7 (35) | 0.11 |
| Intensive care admittance, n (%) | 45 (26.6) | 10 (50) | 0.03 |
| . | Corticosteroids + IVIG . | Corticosteroids + IVIG + anakinra . | P value . |
|---|---|---|---|
| (n = 169) . | (n = 21)a . | ||
| Heart involvement at the end of follow-up, n (%) | 66 (39.1) | 3 (15) | 0.047 |
| Use of vasoactive agents during hospitalization; n (%) | 21 (12.4) | 8 (40) | 0.001 |
| Need of ventilatory support, n (%) | 33 (19.5) | 7 (35) | 0.11 |
| Intensive care admittance, n (%) | 45 (26.6) | 10 (50) | 0.03 |
19 patients were treated with anakinra, CSs and IVIG; 2 patients were treated with anakinra and CSs.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
